NeuroMetrix (NURO) Stock Price, News & Analysis

Company Overview

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $4.33 to $4.69
• 50-Day Range: $4.29 to $4.58
• 52-Week Range: $2.66 to $4.73
• Volume: 35,522 shs
• Average Volume: 15,639 shs
• Market Capitalization: $9.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NURO Stock Analysis - Frequently Asked Questions

How have NURO shares performed this year?

NeuroMetrix's stock was trading at $3.97 at the start of the year. Since then, NURO shares have increased by 14.6% and is now trading at $4.55.
View the best growth stocks for 2025 here.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) posted its quarterly earnings results on Tuesday, November, 5th. The medical device company reported ($0.75) earnings per share (EPS) for the quarter. The medical device company earned $0.59 million during the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 203.71%.

When did NeuroMetrix's stock split?

Shares of NeuroMetrix reverse split on the morning of Wednesday, November 22nd 2023. The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Who are NeuroMetrix's major shareholders?

NeuroMetrix's top institutional investors include Deltec Asset Management LLC (0.89%).
View institutional ownership trends.

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroMetrix investors own include AMC Entertainment (AMC), NIO (NIO), Digital World Acquisition (DWAC), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 6/01/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NURO
• CIK: 1289850
• Web: www.neurometrix.com
• Phone: (781) 890-9989
• Fax: 302-636-5454
• Employees: 20
• Year Founded: 1996

Profitability

• EPS (Most Recent Fiscal Year): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.53 million
• Net Margins: -203.71%
• Pretax Margin: -203.69%
• Return on Equity: -42.56%
• Return on Assets: -39.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.88
• Quick Ratio: 12.70

Sales & Book Value

• Annual Sales: $3.03 million
• Price / Sales: 3.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.18 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 2,060,000
• Free Float: 1,903,000
• Market Cap: $9.37 million
• Optionable: Not Optionable
• Beta: 1.82